Literature DB >> 12133041

An immunocytochemical investigation of human trigeminal nucleus caudalis: CGRP, substance P and 5-HT1D-receptor immunoreactivities are expressed by trigeminal sensory fibres.

D Smith1, R G Hill, L Edvinsson, J Longmore.   

Abstract

5-HT1D (but not 5-HT1B)-receptor immunoreactivity (i.r.) can be detected on trigeminal fibres within the spinal trigeminal tract of the human brainstem. The present study used immunohistochemical and morphometric techniques to determine the proportions of trigeminal fibres expressing substance P, CGRP or 5-HT1D-receptor immunoreactivities. Co-localization studies between 5-HT1D-receptor and substance P- or CGRP-i.r. were also performed. Brainstem material was obtained with consent (four donors) and the total number of immunoreactive fibres within the trigeminal tract was estimated using random field sampling. A greater proportion of fibres (>1 microm diameter) expressed CGRP-i.r. (80 +/- 6%) compared with substance P-i.r. (46 +/- 7%) or 5-HT1D-receptor-i.r. (25 +/- 1%). 5-HT1D-receptor-i.r. was co-localized on some CGRP- or substance P-i.r. fibres. This suggests that 5-HT1D-receptors can regulate the release of CGRP and substance P and may be relevant to the clinical effectiveness of 5-HT1B/1D-receptor agonists in the treatment of migraine and other cranial pain syndromes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12133041     DOI: 10.1046/j.1468-2982.2002.00378.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  16 in total

Review 1.  CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?

Authors:  C S Walker; D L Hay
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 2.  CGRP receptor antagonism and migraine.

Authors:  Lars Edvinsson; Tony W Ho
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

Review 3.  5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?

Authors:  Lars Neeb; Jannis Meents; Uwe Reuter
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

4.  Possible sites of action of the new calcitonin gene-related peptide receptor antagonists.

Authors:  Sajedeh Eftekhari; Lars Edvinsson
Journal:  Ther Adv Neurol Disord       Date:  2010-11       Impact factor: 6.570

Review 5.  CGRP mechanism antagonists and migraine management.

Authors:  Nazia Karsan; Peter J Goadsby
Journal:  Curr Neurol Neurosci Rep       Date:  2015-05       Impact factor: 5.081

6.  Effects of the CGRP receptor antagonist BIBN4096BS on capsaicin-induced carotid haemodynamic changes in anaesthetised pigs.

Authors:  Kapil Kapoor; Udayasankar Arulmani; Jan P C Heiligers; Ingrid M Garrelds; Edwin W Willems; Henri Doods; Carlos M Villalón; Pramod R Saxena
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

7.  Plasma calcitonin gene-related peptide concentration is comparable to control group among migraineurs and tension type headache subjects during inter-ictal period.

Authors:  Ravi Gupta; Tanzeel Ahmed; Basudeb Banerjee; Manjeet Bhatia
Journal:  J Headache Pain       Date:  2009-03-11       Impact factor: 7.277

8.  The effects of the TRPV1 receptor antagonist SB-705498 on trigeminovascular sensitisation and neurotransmission.

Authors:  G A Lambert; J B Davis; J M Appleby; B A Chizh; K L Hoskin; A S Zagami
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-08-19       Impact factor: 3.000

Review 9.  Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system.

Authors:  Andrea Stephanie Link; Anikó Kuris; Lars Edvinsson
Journal:  J Headache Pain       Date:  2008-01-23       Impact factor: 7.277

10.  Electrophysiological properties and chemosensitivity of acutely dissociated trigeminal somata innervating the cornea.

Authors:  T H Veiga Moreira; T D Gover; D Weinreich
Journal:  Neuroscience       Date:  2007-08-15       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.